Valion Bio, Inc. Operating Expenses
Valion Bio, Inc. (VBIO) reported Operating Expenses of $6.42 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-14
- Valion Bio, Inc. operating expenses for the quarter ending 2026-06-30 was $6.42M, a 282.84% increase year-over-year.
- Valion Bio, Inc. operating expenses for the quarter ending 2026-03-31 was $5.63M, a 309.15% increase year-over-year.
- Valion Bio, Inc. operating expenses for the quarter ending 2026-03-30 was $5.63M, a 309.15% increase year-over-year.
- Valion Bio, Inc. operating expenses for the quarter ending 2025-12-31 was $2.02M, a 3436.84% increase year-over-year.
- Valion Bio, Inc. operating expenses for fiscal 2025 was $7.90M, a 76.45% increase from fiscal 2024.
- Valion Bio, Inc. operating expenses for fiscal 2024 was $4.48M, a 47.54% decline from fiscal 2023.
- Valion Bio, Inc. operating expenses for fiscal 2023 was $8.53M, a 17.94% decline from fiscal 2022.
- Valion Bio, Inc. operating expenses for fiscal 2022 was $10.40M, a 85.83% increase from fiscal 2021.
| Period end | Operating Expenses 1 month | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.42M 10-Q · filed 2026-08-14 | $12.06M 10-Q · filed 2026-08-14 | |||||||
| 2026-03-31 | $5.63M 10-Q · filed 2026-05-14 | ||||||||
| 2026-03-30 | $5.63M 10-Q · filed 2026-05-14 | $7.65M derived: sum of 2 quarters · filed 2026-05-14 | $9.99M derived: sum of 3 quarters · filed 2026-05-14 | $11.67M derived: sum of 4 quarters · filed 2026-08-14 | |||||
| 2025-12-31 | $2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $4.35M derived: sum of 2 quarters · filed 2026-03-30 | $6.03M derived: sum of 3 quarters · filed 2026-08-14 | $7.90M 10-K · filed 2026-03-30 | |||||
| 2025-09-30 | $2.34M 10-Q · filed 2025-11-14 | $4.02M derived: sum of 2 quarters · filed 2026-08-14 | $5.88M 10-Q · filed 2025-11-14 | $5.45M derived: sum of 4 quarters · filed 2026-08-14 | |||||
| 2025-06-30 | $1.68M 10-Q · filed 2026-08-14 | $1.99M 10-Q · filed 2025-08-14 | $3.06M 10-Q · filed 2026-08-14 | $3.54M 10-Q · filed 2025-08-14 | $3.11M derived: sum of 3 quarters · filed 2026-08-14 | $4.59M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-03-31 | $1.38M 10-Q · filed 2026-05-14 | $1.56M 10-Q · filed 2025-05-15 | $1.43M derived: sum of 2 quarters · filed 2026-05-14 | $2.91M derived: sum of 3 quarters · filed 2026-05-14 | $4.21M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $57.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.53M derived: sum of 2 quarters · filed 2026-03-30 | $2.83M derived: sum of 3 quarters · filed 2026-03-30 | $4.48M 10-K · filed 2026-03-30 | $5.66M 10-K · filed 2025-03-21 | ||||
| 2024-09-30 | $1.48M 10-Q · filed 2025-11-14 | $2.77M derived: sum of 2 quarters · filed 2025-11-14 | $4.42M 10-Q · filed 2025-11-14 | $4.36M 10-Q · filed 2024-11-14 | $6.67M derived: sum of 4 quarters · filed 2025-11-14 | ||||
| 2024-06-30 | $1.30M 10-Q · filed 2025-08-14 | $1.24M 10-Q · filed 2024-08-14 | $2.94M 10-Q · filed 2025-08-14 | $2.88M 10-Q · filed 2024-08-14 | $5.19M derived: sum of 3 quarters · filed 2025-08-14 | $7.06M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $1.65M 10-Q · filed 2025-05-15 | $3.90M derived: sum of 2 quarters · filed 2025-05-15 | $5.76M derived: sum of 3 quarters · filed 2025-05-15 | $7.95M derived: sum of 4 quarters · filed 2025-05-15 | |||||
| 2023-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $4.12M derived: sum of 2 quarters · filed 2025-03-21 | $6.30M derived: sum of 3 quarters · filed 2025-03-21 | $8.53M 10-K · filed 2025-03-21 | |||||
| 2023-09-30 | $1.87M 10-Q · filed 2024-11-14 | $4.05M derived: sum of 2 quarters · filed 2024-11-14 | $6.28M 10-Q · filed 2024-11-14 | $8.58M derived: sum of 4 quarters · filed 2024-11-14 | |||||
| 2023-06-30 | $2.19M 10-Q · filed 2024-08-14 | $4.42M 10-Q · filed 2024-08-14 | $6.71M derived: sum of 3 quarters · filed 2024-08-14 | $9.36M derived: sum of 4 quarters · filed 2024-08-14 | |||||
| 2023-03-31 | $2.23M 10-Q · filed 2024-05-15 | $4.53M derived: sum of 2 quarters · filed 2024-05-15 | $7.17M derived: sum of 3 quarters · filed 2024-05-15 | $10.32M derived: sum of 4 quarters · filed 2024-05-15 | |||||
| 2022-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $4.95M derived: sum of 2 quarters · filed 2024-03-25 | $8.09M derived: sum of 3 quarters · filed 2024-03-25 | $10.40M 10-K · filed 2024-03-25 | |||||
| 2022-09-30 | $2.65M 10-Q · filed 2023-11-14 | $5.79M derived: sum of 2 quarters · filed 2023-11-14 | $8.10M 10-Q · filed 2023-11-14 | $10.39M derived: sum of 4 quarters · filed 2023-11-14 | |||||
| 2022-06-30 | $3.14M 10-Q · filed 2023-08-14 | $5.45M 10-Q · filed 2023-08-14 | $7.74M derived: sum of 3 quarters · filed 2023-08-14 | $8.95M derived: sum of 4 quarters · filed 2023-08-14 | |||||
| 2022-03-31 | $2.31M 10-Q · filed 2023-05-15 | $4.60M derived: sum of 2 quarters · filed 2023-05-15 | $5.80M derived: sum of 3 quarters · filed 2023-05-15 | $6.83M derived: sum of 4 quarters · filed 2023-05-15 | |||||
| 2022-01-31 | $2.31M 10-Q · filed 2022-05-16 | ||||||||
| 2021-12-31 | $2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $3.49M derived: sum of 2 quarters · filed 2023-03-31 | $4.51M derived: sum of 3 quarters · filed 2023-03-31 | $5.59M 10-K · filed 2023-03-31 | |||||
| 2021-09-30 | $1.20M 10-Q · filed 2022-11-14 | $2.23M derived: sum of 2 quarters · filed 2022-11-14 | $3.31M 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | $1.02M 10-Q · filed 2022-08-15 | $2.10M 10-Q · filed 2022-08-15 | |||||||
| 2021-03-31 | $1.08M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |